Cencora, Inc. (NYSE:COR) Chairman Steven H. Collis Sells 14,578 Shares

Cencora, Inc. (NYSE:COR) Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares of the company’s stock, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Cencora Price Performance

COR stock traded up $2.84 during trading on Wednesday, reaching $271.32. 1,036,117 shares of the company were exchanged, compared to its average volume of 1,378,648. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock’s 50 day moving average price is $251.80 and its 200 day moving average price is $240.46. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $271.74. The company has a market cap of $52.61 billion, a P/E ratio of 38.59, a PEG ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.81%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is 31.29%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on COR shares. StockNews.com raised Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Mizuho started coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target on the stock. Wells Fargo & Company upped their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research note on Friday, March 14th. Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Finally, JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $280.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. JFS Wealth Advisors LLC increased its holdings in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after acquiring an additional 46 shares in the last quarter. Banque Transatlantique SA purchased a new position in shares of Cencora during the 4th quarter worth approximately $29,000. SBI Securities Co. Ltd. acquired a new position in shares of Cencora during the 4th quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC lifted its stake in Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after buying an additional 69 shares in the last quarter. Finally, Kentucky Trust Co acquired a new stake in Cencora during the 4th quarter valued at $33,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.